AsianScientist (Mar. 17, 2014) – Viva Biotech Ltd., a structure-based and fragment-based drug discovery service provider located in Shanghai, and HQL Pharmaceuticals Ltd., based in Rehovot, Israel, have entered into a strategic alliance to jointly provide a fully-integrated drug discovery services, focused on leads generation based on fragment screening.
Under the terms of the agreement, Viva and HQL will jointly provide their customers accelerated and cost effective comprehensive drug discovery services, from targets into early development, with an aim of providing set of diverse high quality novel drug candidates with a wide IP protection for the client’s targets.
The collaboration is based on Viva’s structure-based and fragment-based drug discovery (SBDD/FBDD) capabilities and HQL’s fragments-to-leads breakthrough computational solution.
Dr. Cheney Mao, CEO of Viva, said: “Viva Biotech works on several hundred potential drug targets and runs active FBDD/SBDD drug discovery projects for several dozen major pharmaceutical companies every year. By synergizing our capabilities with HQL’s, we expect to offer our existing and new customers a clear and substantial added value to their projects.”
——
Source: Viva Biotech.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
